Radcliffe Capital Management, L.P. - PHOENIX BIOTECH ACQUISITION ownership

PHOENIX BIOTECH ACQUISITION's ticker is and the CUSIP is 71902K113. A total of 44 filers reported holding PHOENIX BIOTECH ACQUISITION in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Radcliffe Capital Management, L.P. ownership history of PHOENIX BIOTECH ACQUISITION
ValueSharesWeighting
Q3 2023$11,498
+17.1%
150,0000.0%0.00%0.0%
Q2 2023$9,818
+63.4%
150,0000.0%0.00%
Q1 2023$6,008
-99.6%
150,0000.0%0.00%
-100.0%
Q4 2022$1,540,545
+1.8%
150,0000.0%0.05%
+32.4%
Q3 2022$1,514,000
+0.7%
150,0000.0%0.04%
+5.7%
Q2 2022$1,503,000
+0.1%
150,0000.0%0.04%
+2.9%
Q1 2022$1,501,000
+0.9%
150,0000.0%0.03%
-12.8%
Q4 2021$1,487,000150,0000.04%
Other shareholders
PHOENIX BIOTECH ACQUISITION shareholders Q2 2022
NameSharesValueWeighting ↓
MANGROVE PARTNERS IM, LLC 163,538$1,746,5860.12%
Q Global Advisors, LLC 170,785$70.01%
Atalaya Capital Management LP 225,000$9,0000.00%
MMCAP International Inc. SPC 375,000$15,0000.00%
Segantii Capital Management Ltd 5,000$53,4000.00%
DIFESA CAPITAL MANAGEMENT, LP 62,500$2,5060.00%
PERISCOPE CAPITAL INC. 957,098$38,3010.00%
Sage Rock Capital Management LP 91,999$3,6890.00%
Castle Creek Arbitrage, LLC 200,000$8,0000.00%
Context Capital Management, LLC 200,000$80.00%
View complete list of PHOENIX BIOTECH ACQUISITION shareholders